Innate Immunotherapeutics Limited is progressing a drug candidate for the treatment of secondary progressive multiple sclerosis. Recent results from a Phase 2a trial show that the drug is safe, well tolerated, and significantly improved the clinical status of most treated patients. Innate is now planning a phase 2b efficacy trial, which is expected to take 18 months.
The video cannot be shown at the moment. Please try again later.